1. Report Overview
1.1 World IBD Drugs Market: Overview of Findings
1.2 Why You Should Read This Report
1.3 How the Study Delivers
1.4 Main Questions Covered in the Analysis
1.5 Who is this Report For?
1.6 Methods of Research and Analysis
1.6.1 Primary Research
1.6.2 Secondary Research
1.6.3 Market Evaluation and Forecasting Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Reports
1.9 About Visiongain
2. Introduction to the Inflammatory Bowel Disease Drug Market
2.1 What is Inflammatory Bowel Disease (IBD)?
2.2 Classification of IBD
2.3 Symptoms and Diagnosis of IBD
2.4 Multifactorial Causes of IBD
2.5 How Common is IBD?
2.6 What Are the Treatment Options for IBD?
2.6.1 Aminosalicylates - The Most Common Therapy
2.6.2 Antibiotics - Will There Be Any Supporting Evidence Soon?
2.6.3 Corticosteroids - Uptake from Uceris?
2.6.4 Immunomodulators - Slow to Act?
2.6.5 Monoclonal Antibodies - Not Cost-effective?
2.7 Treatment Goals for IBD - Treat-to-Target Approach?
2.8 Treatment Algorithm - is Top-Down Approach the Future Direction?
2.9 Management of Inflammatory Bowel Disease - 2018
3. Global Inflammatory Bowel Diseases Drug Market by Indication, 2019-2029
4. Global Inflammatory Bowel Diseases Drug Market by Drug Class, 2019-2029
4.1 The Inflammatory Bowel Disease Market in 2017 and 2018
4.2 Forecast 2019-2029: Impacted by Biosimilars?
4.3 Biologic Therapies Forecast 2019-2029 - Driving the Market
4.4 Aminosalicylates Forecast 2019-2029: The steady decline
4.5 Antibiotics Forecast 2019-2029: Growing Despite Challenges
4.6 Corticosteroids Forecast 2019-2029: Driven by Uceris
4.7 Immunomodulators Forecast 2019-2029 - Will Grow at Moderate Pace
5. Market Prospects for Leading IBD Drugs, 2019-2029
5.1 Humira (AbbVie) - Growing in the First Half of Forecast Period
5.1.1 Humira: Forecast and Analysis, 2019-2029
5.2 Remicade (Janssen Biotech) - Will Slowly Be Eroded by Biosimilars
5.2.1 Remicade: Forecast and Analysis, 2019-2029
5.3 Cimzia (UCB) - How Will It Fare Against Biosimilars?
5.3.1 Cimzia: Forecast and Analysis, 2019-2029
5.4 Tysabri (Perrigo) - Still Protected by Patent
5.4.1 Tysabri: Forecast and Analysis, 2019-2029
5.5 Asacol (Allergan) - Threat from Generic Competition
5.5.1 Asacol: Forecast and Analysis, 2019-2029
5.6 Pentasa (Shire) - Differentiated by Its Delivery System
5.6.1 Pentasa: Forecast and Analysis, 2019-2029
5.7 Lialda (Shire) - Will Improved Compliance Increase Revenue?
5.7.1 Lialda: Forecast and Analysis, 2019-2029
5.8 Xifaxan (Valeant) - Still Growing Significantly
5.8.1 Xifaxan: Forecast and Analysis, 2019-2029
5.9 Canasa/ Salofalk (Allergan) - Will a Generic Competitor Soon Be Available?
5.9.1 Canasa/Salofalk: Forecast and Analysis, 2019-2029
5.10 Apriso (Valeant) - Challenger to Asacol?
5.10.1 Apriso: Forecast and Analysis, 2019-2029
5.11 Entyvio (Takeda Pharmaceuticals) - Driving the Biologics Segment
5.11.1 Entyvio: Forecast and Analysis, 2019-2029
5.12 Simponi (Janssen Biotech) - Rising Star for the Market?
5.12.1 Simponi: Forecast and Analysis, 2019-2029
5.13 Uceris (Valeant) - Meeting Patients' Needs with Its Delivery System
5.13.1 Uceris: Forecast and Analysis, 2019-2029
6. Global Inflammatory Bowel Disease by Distribution Channel, 2019-2029
7. Leading National Markets: Sales Outlooks, 2019-2029
7.1 IBD Drugs - Leading National Markets 2018
7.2 The US IBD Drug Market, 2019-2029 - The World Leader
7.3 The Japanese IBD Drug Market, 2019-2029 - Growing Significantly?
7.4 The EU-5 IBD Drug Market, 2019-2029 - Driven by the UK
7.5 IBD Drug Markets in BRIC Countries - Taking More Market Share
8. The R&D Pipeline for Inflammatory Bowel Disease
8.1 Top Marketed and pipeline products - Launch dates and Patent expiry
8.2 Interleukin (IL) Inhibitors - One of the Main Areas of Innovation
8.3 Cell-Adhesion Molecule (CAM) Inhibitors - A Promising Avenue
8.3.1 AJG 511 (Ajinomoto Pharmaceutical Co.)
8.3.2 AJM 300 (Ajinomoto Pharmaceuticals)
8.3.3 MEDI 7183/AMG 181 (AstraZeneca)
8.3.4 Etrolizumab (Roche)
8.3.5 PF-00547659 (Pfizer)
8.3.6 Alicaforsen (ISIS 2302, Atlantic Healthcare)
8.3.7 MEDI-2070/AMG 139 (AstraZeneca & Amgen)
8.4 TNF-a Inhibitors - a Specific Target
8.4.1 AVX-470 (Avaxia Biologics)
8.4.2 Ozoralizumab (ALX-0061, Ablynx)
8.5 Stem Cell Therapies - Basis for a Cure?
8.5.1 Ovasave (TxCell)
8.5.2 MultiStem (Athersys and Pfizer)
8.5.3 Prochymal (Remestemcel-L, Osiris Therapeutics)
8.5.4 Cx601 (TiGenix)
8.6 JAK Inhibitors - New Target Pathway
8.6.1 JNJ-54781532 (Janssen)
8.6.2 Xeljanz, (Tofacitinib, CP-690550, Pfizer)
8.7 Toll-like Receptor Agonists
8.7.1 BL-7040 (BioLineRX)
8.7.2 Kappaproct (InDex Pharmaceuticals)
8.8 Other Classes of Agent
8.8.1 Trichuris suis ova (CNDO-201, Coronado Biosciences)
8.8.2 GLPG0974 (Galapagos)
8.8.3 RPC1063 (Receptos/now Celgene)
8.8.4 SGX203 (Soligenix)
8.8.5 Mongersen (GED-0301, Celgene)
8.8.6 Tetomilast (OPC-6535, Otsuka)
8.8.7 Laquinimod (Active Biotech)
8.8.8 RHB-104 (RedHill Biopharma)
8.8.9 Ozanimod (Celgene)
8.8.10 GED-0301 (Celgene)
8.9 Biosimilar Candidates - Promising Competitors of Leading Biologics
8.9.1 Adalimumab Biosimilars
8.9.2 Infliximab Biosimilars
9. Qualitative Analysis of the Inflammatory Bowel Disease Drug Industry and Market
9.1 SWOT and STEP Analysis of the IBD Drugs Market
9.2 What Factors Will Stimulate the IBD Market?
9.2.1 Increasing Disease Incidence in Most National Markets
9.2.2 Better Diagnosis
9.2.3 Delivery Systems Improve Existing Drugs
9.2.4 Biological Drugs - Driving the Market Significantly
9.2.5 Socioeconomic Costs of IBD
9.3 What Factors Will Restrain the Market?
9.3.1 Lack of Understanding of Disease Aetiology
9.3.2 Compliance - Frequent Dosing is Inconvenient
9.3.3 Limitations of Biologics - Side Effect Profiles
9.3.4 The Possible Development of Alternative Treatments
9.3.5 Surgery - Treatment for Recalcitrant IBD
9.3.6 Health Care Cost Containment
10. Leading Companies in the IBD Pharmaceuticals Market
10.1 The Largest Companies by Revenue
10.1.1 AbbVie
10.1.2 Janssen Biotech
10.1.3 Allergan plc
10.1.4 Takeda Pharmaceuticals
10.1.5 Pfizer
10.1.6 Novartis AG
10.1.7 UCB Pharma S.A.
10.1.8 Biogen Inc.
10.1.9 Gilead Sciences, Inc.
10.1.10 Roche
10.1.11 Celgene Corporation
11. Conclusions of the Study
11.1 The IBD Drugs Market Will Expand from 2019 to 2029
11.2 Aminosalicylates and Other Non-Biologic Treatments
11.3 Biological Treatments Dominate the Market
11.4 Improvements Needed in IBD Therapy
11.5 Future IBD Treatments: R&D Efforts Look Promising
11.6 The IBD Sector: Looking to the Future with Confidence
Appendices
Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1 Differentiating Crohn's Disease and Ulcerative Colitis
Table 2.2 Clinical Presentation Crohn's Disease and Ulcerative Colitis
Table 2.3 Worldwide Prevalence Rates for IBD, 2017-2018
Table 2.4 Worldwide Incidence Rates for IBD, 2017-2018
Table 2.5 Geographical Variations in the Incidence of IBD, 2018
Table 2.6 Treatment Recommendations for IBD
Table 2.7 Medical Approach for IBD Management, 2018
Table 2.8 Other Drug Types Used to Treat IBD, 2018
Table 2.9 Aminoacylates for IBD Management, 2018
Table 2.10 Antibiotics for IBD Management, 2018
Table 2.11 Immunomodulators for IBD Management, 2018
Table 2.12 Monoclonal Antibodies for IBD Management, 2018
Table 2.13 Treatment Protocol for IBD, 2018
Table 3.1 Global IBD Drug Market by Indication: Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Segment, 2017 and 2018
Table 3.2 Global IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 4.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Drug Class, 2017 and 2018
Table 4.2 Global IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 4.3 Global IBD Drug Forecast by Segment: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 4.4 Global IBD Drug Market Drivers and Restraints 2019-2029
Table 4.5 Global Biologics Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 4.6 Global Biologic Therapies Drivers and Restraints, 2019-2029
Table 4.7 Global Aminosalicylates Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 4.8 Global Aminosalicylates Drivers and Restraints, 2019-2029
Table 4.9 Global Antibiotics Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 4.10 Global Antibiotics Drivers and Restraints, 2019-2029
Table 4.11 Global Corticosteroids Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 4.12 Global Corticosteroids Drivers and Restraints, 2019-2029
Table 4.13 Global Immunomodulators Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 4.14 Global Immunomodulators Drivers and Restraints, 2018-2028
Table 5.1 Leading IBD Treatments by Revenue ($m), 2018
Table 5.2 Leading IBD Medicines: Revenue Forecasts ($m), AGR (%), 2019-2029
Table 5.3 World Humira Revenue Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 5.4 Drivers and Restraints for Humira, 2019-2029
Table 5.5 World Remicade Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 5.6 Drivers and Restraints for Remicade, 2019-2029
Table 5.7 World Cimzia Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 5.8 Drivers and Restraints for Cimzia, 2019-2029
Table 5.9 World Tysabri Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 5.10 Drivers and Restraints for Tysabri, 2019-2029
Table 5.11 World Asacol Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 5.12 Drivers and Restraints for Asacol, 2019-2029
Table 5.13 World Pentasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 5.14 Drivers and Restraints for Pentasa, 2019-2029
Table 5.15 World Lialda Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 5.16 Drivers and Restraints for Lialda, 2019-2029
Table 5.17 World Xifaxan Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 5.18 Drivers and Restraints for Xifaxan, 2019-2029
Table 5.19 World Canasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 5.20 Drivers and Restraints for Canasa, 2019-2029
Table 5.21 World Apriso Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 5.22 Drivers and Restraints for Apriso, 2019-2029
Table 5.23 World Entyvio Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 5.24 Drivers and Restraints for Entyvio, 2019-2029
Table 5.25 World Simponi Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 5.26 Drivers and Restraints for Simponi, 2019-2029
Table 5.27 World Uceris Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 5.28 Drivers and Restraints for Uceris, 2019-2029
Table 6.1 World Inflammatory Bowel Disease by Distribution Channel Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.1 IBD Drug Revenues ($m) by Leading Country, 2018
Table 7.2 US IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.3 US IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.4 US IBD Drug Market Forecast by Drug Class: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.5 US IBD Drug Market Forecast by Distribution Channel: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.6 Japanese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.7 Japanese IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.8 Japan IBD Drug Market Forecast by Drug Class: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.9 Japan IBD Drug Market Forecast by Distribution Channel: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.10 EU5 IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.11 German IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.12 German IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.13 German IBD Drug Market Forecast by Drug Class: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.14 German IBD Drug Market Forecast by Distribution Channel: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.15 French IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.16 French IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.17 French IBD Drug Market Forecast by Drug Class: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.18 French IBD Drug Market Forecast by Distribution Channel: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.19 UK IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.20 UK IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.21 UK IBD Drug Market Forecast by Drug Class: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.22 UK IBD Drug Market Forecast by Distribution Channel: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.23 Spanish IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.24 Spanish IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.25 Spanish IBD Drug Market Forecast by Drug Class: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.26 Spanish IBD Drug Market Forecast by Distribution Channel: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.27 Italian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.28 Italian IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.29 Italian IBD Drug Market Forecast by Drug Class: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.30 Italian IBD Drug Market Forecast by Distribution Channel: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.31 BRIC IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.32 Brazilian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.33 Brazilian IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.34 Brazilian IBD Drug Market Forecast by Drug Class: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.35 Brazilian IBD Drug Market Forecast by Distribution Channel: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.36 Russian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.37 Indian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 7.38 Chinese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 8.1 Key Patents for marketed and pipeline products
Table 8.2 Biologics and biosimilars approved for treatment in IBD
Table 8.3 Biologics in the pipeline and their current status
Table 8.4 Biosimilars in the pipeline and their current status
Table 8.5 Selected IL Inhibitors in Clinical Development, 2018
Table 8.6 Selected CAM Inhibitors in Clinical Development, 2018
Table 8.7 Selected TNF-a Inhibitors in Clinical Development, 2018
Table 8.8 Selected Stem Cell Therapies in Clinical Development, 2018
Table 8.9 Selected JAK Inhibitors in Clinical Development, 2018
Table 8.10 Selected Toll-like Receptor Agonist in Clinical Development, 2018
Table 8.11 Selected Other Classes in Clinical Development, 2018
Table 9.1 Strengths, Weaknesses, Opportunities and Threats in the IBD Drug Market
Table 9.2 Social, Technological, Economic and Political Forces on the IBD Drug Market
Table 10.1 AbbVie Revenues ($m) and Market Share (%), 2018
Table 10.2 Janssen Biotech Revenues ($m) and Market Share (%), 2018
Table 10.3 Allergan Revenues ($m) and Market Share (%), 201
Table 10.4 Takeda Revenues ($m) and Market Share (%), 2018
Table 10.5 Pfizer Revenues ($m) and Market Share (%), 2018
Table 10.5 UCB Pharma S.A Revenues ($m) and Market Share (%), 2018
Table 10.7 Biogen Inc. Revenues ($m) and Market Share (%), 2018
Table 11.1 Global IBD Revenue Forecasts ($m), Market Share (%) by Product Category, 2019, 2024, 2029
Table 11.2 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Region, 2019, 2024, 2029
Table 11.3 Summary of IBD Market Drivers and Restraints, 2019-2029
List of Figures
Figure 1.1 Inflammatory Bowel Disease Market Segmentation, 2018
Figure 3.1 Global IBD Drug Market Forecast by Indication ($m), 2019-2029
Figure 4.1 World IBD Drugs Market Shares by Drug Class (%), 2018
Figure 4.2 Global IBD Drug Market Forecast ($m), 2019-2029
Figure 4.3 World IBD Drugs Market Shares by Drug Class (%), 2029
Figure 4.4 Global Biologics Forecast for IBD Market ($m), 2019-2029
Figure 4.5 Global Aminosalicylates Forecast for IBD Market ($m), 2019-2029
Figure 4.6 Global Antibiotics Forecast for IBD Market ($m), 2019-2029
Figure 4.7 Global Corticosteroids Forecast for IBD Market ($m), 2019-2029
Figure 4.8 Global Immunomodulators Forecast for IBD Market ($m), 2019-2029
Figure 5.1 World Humira Revenue Forecast ($m), 2019-2029
Figure 5.2 World Remicade Forecast ($m), 2019-2029
Figure 5.3 World Cimzia Forecast ($m), 2019-2029
Figure 5.4 World Tysabri Forecast ($m), 2019-2029
Figure 5.5 World Asacol Forecast ($m), 2019-2029
Figure 5.6 World Pentasa Forecast ($m), 2019-2029
Figure 5.7 World Lialda Forecast ($m), 2019-2029
Figure 5.8 World Xifaxan Forecast ($m), 2019-2029
Figure 5.9 World Canasa Forecast ($m), 2019-2029
Figure 5.10 World Apriso Forecast ($m), 2019-2029
Figure 5.11 World Entyvio Forecast ($m), 2019-2029
Figure 5.12 World Simponi Forecast ($m), 2019-2029
Figure 5.13 World Uceris Forecast ($m), 2019-2029
Figure 6.1 World Inflammatory Bowel Disease by Distribution Channel Forecast, 2019-2029
Figure 7.1 Global IBD Drug Market by Leading Country (%), 2019
Figure 7.2 Global IBD Drug Market by Leading Country (%), 2029
Figure 7.3 US IBD Drug Market Forecast ($m), 2019-2029
Figure 7.4 US IBD Drug Market Forecast by Indication Forecast, ($m), 2019-2029
Figure 7.5 US IBD Drug Market by Drug Class Forecast, ($m), 2019-2029
Figure 7.6 US IBD Drug Market by Distribution Channel Forecast, ($m), 2019-2029
Figure 7.7 Japanese IBD Drug Market Forecast ($m), 2019-2029
Figure 7.8 Japanese IBD Drug Market Forecast by Indication ($m), 2019-2029
Figure 7.9 Japanese IBD Drug Market Forecast by Drug Class ($m), 2019-2029
Figure 7.10 Japanese IBD Drug Market Forecast by Distribution Channel ($m), 2019-2029
Figure 7.11 EU5 IBD Drug Market Forecasts ($m), 2019-2029
Figure 7.12 German IBD Drug Market Forecast ($m), 2019-2029
Figure 7.13 German IBD Drug Market Forecast by Indication ($m), 2019-2029
Figure 7.14 German IBD Drug Market Forecast by Drug Class($m), 2019-2029
Figure 7.15 German IBD Drug Market Forecast by Distribution Channel ($m), 2019-2029
Figure 7.16 French IBD Drug Market Forecast ($m), 2019-2029
Figure 7.17 French IBD Drug Market Forecast by Indication ($m), 2019-2029
Figure 7.18 French IBD Drug Market Forecast by Drug Class ($m), 2019-2029
Figure 7.19 French IBD Drug Market Forecast by Distribution Channel ($m), 2019-2029
Figure 7.20 UK IBD Drug Market Forecast ($m), 2019-2029
Figure 7.21 UK IBD Drug Market Forecast by Indication ($m), 2019-2029
Figure 7.22 UK IBD Drug Market Forecast by Drug Class ($m), 2019-2029
Figure 7.23 UK IBD Drug Market Forecast by Distribution Channel ($m), 2019-2029
Figure 7.24 Spanish IBD Drug Market Forecast ($m), 2019-2029
Figure 7.25 Spanish IBD Drug Market Forecast by Indication ($m), 2019-2029
Figure 7.26 Spanish IBD Drug Market Forecast by Drug Class ($m), 2019-2029
Figure 7.27 Spanish IBD Drug Market Forecast by Distribution Channel ($m), 2019-2029
Figure 7.28 Italian IBD Drug Market Forecast ($m), 2019-2029
Figure 7.29 Italian IBD Drug Market Forecast by Indication ($m), 2019-2029
Figure 7.30 Italian IBD Drug Market Forecast by Drug Class ($m), 2019-2029
Figure 7.31 Italian IBD Drug Market Forecast by Distribution Channel ($m), 2019-2029
Figure 7.32 BRIC IBD Drug Market Forecasts ($m), 2019-2029
Figure 7.33 Brazilian IBD Drug Market Forecast ($m), 2019-2029
Figure 7.34 Brazilian IBD Drug Market Forecast by Indication ($m), 2019-2029
Figure 7.35 Brazilian IBD Drug Market Forecast by Drug Class ($m), 2019-2029
Figure 7.36 Brazilian IBD Drug Market Forecast by Distribution Channel ($m), 2019-2029
Figure 7.37 Russian IBD Drug Market Forecast ($m), 2019-2029
Figure 7.38 Indian IBD Drug Market Forecast ($m), 2019-2029
Figure 7.39 Chinese IBD Drug Market Forecast ($m), 2019-2029
Figure 10.1 AbbVie Assets (Immunology, Hematologic Oncology, Neuroscience, Virology and Targeted Opportunities) - Marketed and Pipeline 2018
Figure 10.2 AbbVie Assets (Immunology) - Marketed and Pipeline 2018
Figure 10.3 AbbVie Deals and Partnerships 2011 - 2017
Figure 10.4 Janssen Assets - Marketed and Pipeline 2018
Figure 10.5 Janssen - Deals and Partnerships 2011 - 2017
Figure 10.6 Janssen - Inflammatory Bowel Disease Pipeline Products 2018-2019
Figure 10.7 Allergan Assets - Marketed and Pipeline 2018
Figure 10.8 Allergan - Deals and Partnerships 2011 - 2018
Figure 10.9 Takeda - Major Areas: ~75% of Total Sales Concentrated in Five Areas
Figure 10.10 Takeda Assets - Marketed and Pipeline 2018
Figure 10.11 Shire - Deals and Partnerships 2011 - 2018
Figure 10.12 Pfizer Assets - Marketed and Pipeline 2018
Figure 10.13 Novartis AG Assets - Marketed and Pipeline 2018
Figure 10.14 UCB Pharma A.S. Assets - Marketed and Pipeline 2018
